pentobarbital will lower the extent or effect of temsirolimus by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
Also speedy administration could cause respiratory melancholy, laryngospasm, apnea, or vasodilation with drop in blood pressure level
pentobarbital will decrease the level or influence of mestranol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lessen the level or outcome of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Powerful CYP3A4 inducers may well reduce suvorexant efficacy; if increased suvorexant dose expected, usually do not exceed 20 mg/day
pentobarbital will decrease the level or outcome of voriconazole by influencing hepatic enzyme CYP2C9/10 metabolism. Small/Significance Not known.
CYP3A4 inducers may perhaps improve the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely keep track of individuals having ifosfamide with CYP3A4 inducers for toxicities and contemplate dose adjustment.
pentobarbital will lessen the level or effect of zonisamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.
pentobarbital will minimize the extent or outcome of fentanyl by more info influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead to the lower in fentanyl plasma concentrations, deficiency of efficacy or, quite possibly, progress of the withdrawal syndrome inside of a affected individual who's got created physical dependence to fentanyl.
pentobarbital will decrease the level or result of conjugated estrogens, vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will reduce the extent or result of sufentanil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will lower the extent or influence of tramadol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Diminished AUC of tramadol as well as active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers
pentobarbital will reduce the extent or impact of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will decrease the extent or influence of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
pentobarbital will minimize the level or result of exemestane by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. For people receiving exemestane that has a potent CYP3A4 inducer the recommended dose of exemestane is fifty mg each day following a meal.